Regarding the analysis of the approved dosing regimen for maintenance therapy in PNH using crovalimab, eculizumab, and ravulizumab, Table 2 quantifies the average amount of C5 neutralized by a single molecule of each antibody. The gene discussed is C5; the disease is paroxysmal nocturnal hemoglobinuria.